ACTG 384 is a randomized trial of combination regimens for initial treatment of HIV infection. A5005s is a metabolic substudy of ACTG 384 which will examine changes in glucose metabolism, lipid metabolism, and body composition associated with highly active antiretroviral therapy.
Showing the most recent 10 out of 565 publications